FRLN - Why Is Gene Therapy Player Freeline Therapeutics Stock Trading Higher Today? | Benzinga
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) reported initial data from the ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease.
Gaucher disease is a genetic disorder in which a deficiency of the GCase enzyme leads to a buildup of harmful substrates, causing symptoms including enlarged spleen and liver, low blood counts, bone pain, and reduced lung function.
Data from the ...